Recent Pfizer Press Releases

  • 1/22/08 6:00 am EST

    With Millions of U.S. Dogs Overweight or Obese, and Most Owners Unaware of the Problem, Veterinarians Lend Helping Hand With First-Ever National Canine Weight Check This February

    NEW YORK--(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it’s time for dog owners to make a similar pledge for their furry friends. Recent studies indicate that 25 to 40 percent of U.S. dogs – approximately 17 million – are overweight or obese and potentially facing serious health problems. What’s more troubling is thatmore...
  • 1/18/08 11:25 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at 8:30a.m. Eastern Standard Time. The purpose of the meeting is to discuss the Company’s strategic direction. Jeffrey B. Kindler, Pfizer chairman and chief executive officer, will host the meeting. To view and listen to the webcast, visit our web sitemore...
  • 1/18/08 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United States, with more than 438,000 U.S. deaths annually attributable to smoking. Patients who smoke cigarettes should be counseled to quit. CHANTIX® was approved in May of 2006 in the U.S. as an aid to smoking cessation. Based upon post-marketing reportsmore...
  • 1/16/08 12:04 pm EST

    Pfizer Partners With 17 Nonprofit Organizations Sending 28 Fellows to Help Address Systemic Health Care Challenges in the Developing World

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who will partner with non-governmental organizations (NGOs) and multilateral organizations (MLOs) in developing countries to help build health care infrastructure while on dedicated 4-6 month assignments. The Pfizer Global Health Fellows program is one of the first public-more...
  • 1/16/08 11:38 am EST
    NEW YORK--(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering treatment maintained a significant 36 percent reduction in the relative risk of fatal or non-fatal heart attacks over five years, according to a new analysis. This was a post-hoc analysis (designed and completed following the closure of the trial) of the lipid-lowering arm of the Anglo-Scandinavian Cardiacmore...
  • 1/16/08 4:00 am EST
    NEW YORK & MARTINSRIED, Germany--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligiblemore...
  • 1/15/08 9:00 am EST
    NEW YORK--(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond to exercise and diet. Since Pfizer Animal Health’s SLENTROLTM was introduced eight months ago in the U.S., thousands of obese dogs have benefited from healthier weights and more active lives. Now, European vets will be able to talk to dog owners about Slentrol asmore...
  • 1/14/08 10:40 am EST

    One of the Largest Observational Studies of Cardiovascular Outcomes Published Today Online in Clinical Therapeutics Journal

    NEW YORK--(BUSINESS WIRE)-- Results of an observational study of a large U.S. managed care claims database showed that new statin users without cardiovascular disease who took Lipitor® (atorvastatin calcium) Tablets had a significantly lower relative risk of experiencing any cardiovascular event, a heart attack, or revascularization (a type of heart surgery) compared to patients who took simvastatin. Patients taking Lipitor had amore...
  • 1/14/08 7:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 basic patent for Lipitor, initially rejecting the patent’s claims. This initial action, which is how the Office raises its issues with the patentee, will now be followed by the company’s response, in which Pfizer will address those issues raised by the examiner. As themore...
  • 1/9/08 6:23 pm EST

    Decision Consistent With Similar Ruling in Federal Court in November 2007

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer’s Celebrex medication. New York Supreme Court Justice Shirley W. Kornreich ruled that the plaintiffs suing Pfizer in New York failed to present reliable scientific evidence necessary to prove that Celebrex can cause heart attacks and strokes at 200 mg daily – the mostmore...